Clinical Trials Logo

Nicotine Dependence clinical trials

View clinical trials related to Nicotine Dependence.

Filter by:

NCT ID: NCT00133757 Completed - Nicotine Dependence Clinical Trials

Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers

Start date: June 2005
Phase: Phase 1
Study type: Interventional

In this study we, the investigators at the Centre for Addiction and Mental Health, intend to explore whether bupropion is able to reduce smokers' responses to cigarette-related environmental cues, and craving. Previous studies have indicated that bupropion may be able to achieve these outcomes. Therefore, we predict that smokers treated with bupropion for several weeks will show reduced reactivity to cigarette cues and craving.

NCT ID: NCT00129246 Completed - Smoking Clinical Trials

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

Start date: December 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.

NCT ID: NCT00108173 Completed - Nicotine Dependence Clinical Trials

Brain Reaction to Treatment of Nicotine Dependence

Start date: October 2002
Phase: Phase 1
Study type: Interventional

The purpose of the study was to determine how the treatments for cigarette craving work. Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after placebo.

NCT ID: NCT00105482 Completed - Nicotine Dependence Clinical Trials

Targeted Interventions for Weight-Concerned Smokers

Start date: January 2005
Phase: Phase 2
Study type: Interventional

Weight gain after quitting smoking is an important barrier to treatment for many smokers. This study will test a drug called naltrexone with weight-concerned smokers to investigate whether or not this drug both improves smoking cessation quit rates and minimizes post quit weight gain.